Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer
Status:
Not yet recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This is a multi-center, single-arm study to investigate the efficacy and safety of liposomal
irinotecan+5-FU/LV+ bevacizumab as second-line therapy in metastatic colorectal cancer in
Chinese population.